Related Experiment Video
Updated: May 14, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Antimicrobial Activity of D-Form Synthetic Peptides Against Metronidazole-Resistant and Susceptible Trichomonas
Özben Özden1, Tuba Polat1, Tanıl Kocagöz1,2
1Graduate School of Health Sciences, Department of Medical Biotechnology, Acibadem University, Istanbul 34752, Türkiye.
Abstract:
Trichomonas vaginalis is the causative agent of trichomoniasis, the most common non-viral sexually transmitted infection worldwide. In these cases, 5-Nitroimidazoles, particularly metronidazole (MTZ), remain the primary treatment option; however, resistance to MTZ has been increasingly reported. This study aimed to evaluate the in vitro activity of D-form synthetic antimicrobial peptides and investigate transcriptional differences associated with MTZ resistance and peptide treatment in T. vaginalis. D-form synthetic peptides (D-TN1, D-TN3, and D-TN6) developed in the R&D Laboratory of Acibadem University were tested against metronidazole-susceptible (T. vaginalis ATCC 30236) and metronidazole-resistant (T. vaginalis ATCC 50143) strains by minimum lethal concentration (MLC) assays. D-TN1 exhibited an MLC of 16 µg/mL in both strains, whereas D-TN3 and D-TN6 exhibited MLC values of 32 µg/mL and 16-32 µg/mL, respectively. Comparative transcriptomic analysis was conducted to investigate transcriptional differences. Differential gene expression analysis identified 3395 genes between the resistant and susceptible isolates and 3060 genes in the D-TN1-treated resistant isolate (FDR < 0.05, |log2FC| ≥ 1). D-TN1 treatment in the resistant isolate was associated with downregulation of ribosomal and metabolic pathways. If confirmed with further in vivo studies, this new antimicrobial peptide may become a new therapeutic alternative in the treatment of trichomoniasis in the future.
Insights
New antimicrobial peptides show promise against metronidazole-resistant Trichomonas vaginalis, the cause of trichomoniasis. D-TN1 peptide effectively killed both susceptible and resistant strains in vitro, suggesting a potential new treatment for this common STI.
Area of Science:
- Antimicrobial Peptides
- Parasitic Infections
- Drug Resistance
Background:
- Trichomoniasis, caused by *Trichomonas vaginalis*, is the most common non-viral sexually transmitted infection globally.
- Metronidazole (MTZ) is the primary treatment, but MTZ resistance in *T. vaginalis* is a growing concern.
- Novel therapeutic strategies are needed to combat resistant strains of *T. vaginalis*.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of D-form synthetic peptides against *T. vaginalis*.
- To investigate transcriptional changes associated with MTZ resistance and peptide treatment in *T. vaginalis*.
- To identify potential new therapeutic alternatives for trichomoniasis.
Main Methods:
- Minimum Lethal Concentration (MLC) assays were performed using D-form synthetic peptides (D-TN1, D-TN3, D-TN6) against MTZ-susceptible and MTZ-resistant *T. vaginalis* strains.
- Comparative transcriptomic analysis was conducted on MTZ-resistant and susceptible isolates.
- Differential gene expression analysis was performed on MTZ-resistant isolates before and after D-TN1 treatment.
Main Results:
- D-TN1 demonstrated potent in vitro activity with an MLC of 16 µg/mL against both MTZ-susceptible and MTZ-resistant *T. vaginalis* strains.
- Differential gene expression analysis revealed significant transcriptional differences between resistant and susceptible isolates (3395 genes).
- D-TN1 treatment in resistant isolates led to the downregulation of ribosomal and metabolic pathways (3060 genes).
Conclusions:
- D-form synthetic antimicrobial peptides, particularly D-TN1, exhibit significant in vitro efficacy against *T. vaginalis*, including MTZ-resistant strains.
- Transcriptomic analysis provides insights into the molecular mechanisms underlying MTZ resistance and peptide action.
- D-TN1 represents a promising candidate for a novel therapeutic agent against trichomoniasis, warranting further in vivo investigation.
Related Concept Videos
Antimicrobial Effectiveness
Clinical Significance of Antibiotic Resistance
Inhibitors of Bacterial Protein Synthesis
Antibiotic Selection
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Inhibitors of Gram-positive Cell Wall Synthesis
